Premarket Biotech Digest – AVGR Announces Positive Data, CXRX To Be Investigated


Jazz Pharmaceuticals (JAZZ) announced receiving the FDA approval for the Priority Review of its  New Drug Application (NDA) seeking approval of Breakthrough Therapy-tagged VYXEOS (cytarabine and daunorubicin) for the treatment of acute myeloid leukemia. The review status helps to shorten the review clock to six months.

Cytori Therapeutics (CYTX) announced that the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authorityhas exercised its rights under Option 2 of its contract with the company for the development of Cytori Cell Therapy (DCCT-10) as an adjunct therapy in thermal burn injury. As per the agreement, BARDA will pay Cytori $13.4 million for reimbursement of development costs plus a fixed fee.

Deals and Collaborations

NanoString Technologies (NSTG) announced inking a new deal for selling 2.75 million shares of its common stock. The stock is being sold to underwriter Robert Baird & Co. and the agreement includes a 30-day option to buy an additional 412.5K shares. The company intends to use the net proceeds for the purpose of funding working capital and general corporate purposes.

EntroMedics (ETRM) announced its first vBloc implant at AMITA Health Adventist Medical Center in Bolingbrook, IL.. The implant is a pacemaker-like device that delivers vagal nerve blocking therapy via electrodes.

1 2
View single page >> |

Subscribe to KKD Healthcare Analytics for an entire Biotech digest. 

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.